Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs. Immunogenicity refers to the immune response generated by the immune system against drugs entering the human body. The immune response produces anti-drug antibodies (ADA) that specifically bind to drug molecules. In the process of drug development, especially for macromolecular drugs, small molecule and peptide drugs, and even related adjuvants, they may directly or indirectly cause a large immunogenic reactions. Mild reactions may lead to the termination of projects in the preclinical or clinical stages, resulting in the loss of early economic investments. Severe reactions may reduce drug efficacy, cause allergic reactions, and even pose a threat to life safety. According to current FDA guidelines, all serious immune responses, inclu...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services